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Throughout the last decade, thousands of refugees arrived on a
daily basis at the Mediterranean coast of Southern European
countries. Because this influx is not expected to slow down, the
development of national and European strategies is required to
ensure appropriate and accessible health care to these vulner-
able populations.1,2 The vast majority of these migrants come
from areas in which sickle cell disease (SCD) and other hemo-
globinopathies are highly prevalent. Limited data are available
on the burden of these disorders in populations of refugees.
Here, we present 2 pieces of evidence supporting the need for
specific strategies for the early identification of SCD in refugees.
First, we carried out a retrospective study of data collected from
2014 to 2017 across 13 Italian reference centers for SCD and
hemoglobinopathies. The primary outcome of this study was to
identify events associated with the new diagnosis of SCD in
refugees; the secondary outcome was to evaluate the impact of
hemoglobinopathies in refugees coming from endemic areas.
The descriptive analysis of variables was performed with counts,
percentages, mean and standard deviation (SD), or median and
interquartile range (IQR; 25th-75th percentile). Then, we discuss
the results of a pilot study that screened all refugees seen in a
single second-level refugee center duringOctober 2017, using 1
of the new rapid point-of-care screening devices (Sickle SCAN;
BioMedomics). The aim was to fast-track the care of individuals
with SCD and the collection of relevant demographic data.3-5
The results were validated by high-performance liquid chro-
matography, the standard gold-standard screening method.3-5
Based on data from the Italian Ministry of the Interior, a total of
624 688 refugees landed on the Italian coast between 2014 and
2017 (Figure 1A).6 Refugees from Syria represented only 4% to
25% of these each year (Figure 1A-B), whereas 21% to 53% came
from sub-Saharan African countries (21% in 2014, 31% in 2015,
53% in 2016, and 46% in 2017). Refugees generally disembark
at known hotspots on the coast of Southern Italy. They are
then relocated in second-level reception centers throughout
the country, before being screened for communicable diseases
and undergoing the vaccination program recommended by the
World Health Organization within 2 weeks of their arrival.
Screening for noncommunicable disorders, such as SCD, is not
conducted. SCD is a common red cell disorder identified as a
global health priority by the African Union and the World Health
Organization.7,8 Life-threatening complications of SCD include
acute vaso-occlusive painful events, acute chest syndrome, and
splenic sequestration, which require early identification and in-
tensive clinical management. In addition, dehydration, psycho-
logical stress, and exposure to high/low temperatures can trigger
vaso-occlusive events in patients with SCD. Refugees represent
marginalized and vulnerable people who are exposed to extreme
conditions during their travels, mostly through Africa, to the
coast of Southern European countries. The delay in the identi-
fication of SCD may lead to severe acute organ complications
and fatal outcomes.9,10 To help manage acute health problems
related to SCD that might dominate the first phase of transition
of refugees, we have developed an algorithm for the man-
agement of acute events in the emergency department (ED) and
we promoted specific knowledge of SCD, with training sessions
and seminars dedicated to physicians in EDs, pediatricians,
hematologists, and internal medicine physicians.10
Our retrospective study shows that SCD is relatively common in
refugees visiting EDs for acute sickle cell–related events. Over
the 4 years studied, we identified 70 patients with hemoglo-
binopathies: 50% were adults (86% male; 14% female; median
age, 21 years; IQR, 18.5-19 years), and 50% were children (80%
male; 20% female; median age, 10 years; IQR, 1-16 years). The
number of refugees with SCD arriving in Italy between 2014 and
2017 revealed a peak in 2016 (48%) corresponding to the arrival
of a large number of refugees from sub-Saharan Africa (41%)
(Figure 1). The overall genotypic distribution was as follow:
SS (n5 49), SC (n5 9), Sb-thalassemia (n5 3), CC (n5 2), AS (n5
1), and transfusion-dependent b-thalassemia (TDT; n 5 6). The
analysis of genotypes combinedwith patient origin revealed that
61.4% of the SS individuals identified were from sub-Saharan
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Africa (Figure 1C). SC patients were mainly from West African
countries, whereas TDT patients were from Syria (7.1%) and
Bangladesh (1.4%) (Figure 1C). As shown in Figure 2A, acute
events were primarily responsible for the identification of SCD in
refugees. The main reasons for access to ED of previously un-
diagnosed SCD were qualitatively similar to those seen in the
native Italian SCD population11 or other SCD groups,12,13 with
the exception of anemia, which was the second main cause of
visits to the ED in our study population. Although we did not
have access to historical patient hematologic data, we cannot
exclude the possible contribution of malnutrition to anemia
in refugees with SCD. Among the individuals with SCD for
whom hemoglobin (Hb) data were recorded (n 5 46), 15% had
Hb levels ,8 g/dL, and 85% had Hb levels $8 g/dL. This is
consistent with a recent report of data from German refugee
centers, in which anemia was recognized in 22.5% of the refu-
gees.14 A total of 82.9% of patients was diagnosed with SCD
within the first 11 months after their arrival in Italy, and 14.3%
were diagnosed during the second year. The main identifying
signs of SCD in our group of patients are summarized in Figure
2A; in a small group, SCD was also identified outside acute
events. Among these, 2.9% were identified through early
pregnancy counseling or through the management of preg-
nancy complications related to severe clinical manifestations
due to SCD (venous cerebral thrombosis, 1.4%) or obstetrical
complications (spontaneous abortion, 1.4%).15 Collectively, our
results indicate the need for screening for SCD in refugees at their
arrival to prevent severe acute and life-threatening clinical mani-
festations. This is also supported by a document from the Di-
vision of Global Migration andQuarantine of the US Department
of Health and Human Services,16 as well as by the introduction
of SCD screening by Canadian health authorities because of
the increasing prevalence of SCD related to migration fluxes
in North America.17 Indeed, our prospective study screening
asymptomatic refugees in a second-level refugee center iden-
tified 3%SCDpatients and 20%AS individuals over 400 screened
individuals. The analysis of genotypes, combined with data on
patients’ origins, revealed that 2.6% of SCD patients were from
sub-Saharan Africa. HbS carriers were from Nigeria (11.5%),
Guinea (2.6%), Ivory Coast (2.1%), and Senegal (1.6%), whereas
0.5% each were from Burkina Faso, Gambia, Ghana, and Guinea
Bissau; HbC carriers were from Ivory Coast (1%), Ghana (1%),
Guinea (1%), Mali (0.5%) and Nigeria (0.5%); HbD carriers were
from Nigeria (0.5%); and the b-thalassemia carriers were from
Gambia (0.5%) and Guinea (0.5%). A total of 71.4% of the indi-
viduals screened did not have any hemoglobinopathy. None
of the newly identified SCD patients were aware of their condition.
Because SCD and b-thalassemia are endemic to several parts
of Italy, a national network of reference centers has been estab-
lished in the last 5 decades for the clinical management of
these patients, ensuring preconception counseling and prenatal
diagnosis.18 In addition, this network allowed the identification






































































































Figure 1. Numbers and country of origin of refugees in Italy with new identified severe hemoglobinopathy. (A) Numbers of total refugees in Italy, refugees from the
sub-Saharan area, and refugees from Syria in the period between 2014 and 2017. (B) Map showing the influxes of refugees identified with hemoglobinopathies (SCD or TDT)
after their arrival in Italy between 2014 and 2017. Countries of origin are shown in dark gray. The number of refugees from a country is proportional to the width and saturation
of each line. (C) Numbers of patients with hemoglobinopathies (SCD or TDT) differentiated by genotype, as a function of nationality.
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This makes the Italian experience unique compared with other
European countries with a lower incidence of SCD. In our study,
refugees with SCD were all redirected to the comprehensive
SCD centers of the area. 60% of them were admitted or referred
to an SCD center within 11 months after their first visit to an ED,
and 32.9% within the second year. Patients with SCD were
treated with hydroxyurea and followed-up by the comprehen-
sive SCD centers of the area. A multidisciplinary working group
on health care in refugees is now analyzing the possibility of
introducing routine screening of SCD as a noncommunicable
disorder in refugees.
In conclusion, our data support the recommendation that ref-
ugees coming from areas endemic for SCD should be screened
for the disease. To appropriately address this problem and to
face the dynamic changes in the distribution and prevalence of
SCD in European countries, we propose (1) the development
of flow charts facilitating the early and systematic identification
of SCD in refugees at their arrival or in second-level refugee
camps; (2) to educate health professionals, such as ED physicians,
pediatricians, internal medicine doctors, and hematologists, about
the early identification and treatment of acute vaso-occlusive
events; (3) to rapidly refer refugees with SCD or symptomatic
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Figure 2. In refugees, the identification of new patientswith severe hemoglobinopathymight result from the intersection of patients with acute events and screening
programs for individuals from endemic areas. (A) Type and frequency of acute and nonacute events in refugees allowing the identification of a severe hemoglobinopathy
in Italy between 2014 and 2017. *Other includes cardiopathy (n 5 1), seizures (n 5 1), splenic infarction and thrombosis of central retinal vein (n 5 1), left gonalgia in severe
gonarthrosis and joint deformities in septic arthritis outcomes (n5 1), inconsolable crying of a baby (n5 1), and genetic counseling for the second pregnancy of a mother
(n 5 1). (B) Percentages or patients screened, in a second-level refugee center with the new point-of-care screening device, as a way of fast-tracking the individuals with
SCD, differentiated by genotype, as a function of nationality.
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HbS-carrier refugees to the comprehensive SCD reference center
for treatment and follow-up; and (4) to rapidly start disease-
modifying treatment, such as hydroxyurea. These actions will allow
for the earlier identification of patients with SCD, preventing
severe complications and decreasing the overall health care
costs associated with this population.
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